Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Genetics

Topic: Brain proteins, microglia and lab models

Plain-language summary

The risk of developing Alzheimer's disease (AD) significantly increases in individuals carrying the APOEε4 allele. Pathway analysis of the genes harboring these variants showed significant enrichment in extracellular matrix (ECM)-related processes, suggesting protective effects of functional modifications in ECM proteins. Brain expression of cognitively unaffected homozygous APOEε4 carriers had significantly lower FN1 deposition and less reactive gliosis compared to homozygous APOEε4 carriers with AD, suggesting that FN1 might be a downstream driver of APOEε4-mediated AD-related pathology and cognitive decline. To validate our findings, we used zebrafish models with loss-of-function (LOF) mutations in fn1b-the ortholog for human FN1. We found that fibronectin LOF reduced gliosis, enhanced gliovascular remodeling, and potentiated the microglial response, suggesting that pathological accumulation of FN1 could impair toxic protein clearance, which is ameliorated with FN1 LOF. Our study suggests that vascular deposition of FN1 is related to the pathogenicity of APOEε4, and LOF variants in FN1 may reduce APOEε4-related AD risk, providing novel clues to potential therapeutic interventions targeting the ECM to mitigate AD risk.

What this study adds

Evidence grade: Moderate

This is a case-control study of 7,185 participants. This study found that rare variants in the FN1 gene may reduce Alzheimer risk related to APOE ε4, and zebrafish experiments suggested fibronectin loss-of-function reduced gliosis and improved clearance of toxic proteins. Reported effect size: OR 0.29 (95% CI 0.11-0.78) for AD among APOE ε4 homozygotes carrying FN1 rs140926439; onset delayed 3.37 years.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bhattarai, P., Gunasekaran, T. I., Belloy, M. E., Reyes-Dumeyer, D., Jülich, D., Tayran, H., et al. (2024). Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer's disease. Acta Neuropathologica. https://doi.org/10.1007/s00401-024-02721-1

Vancouver

Bhattarai P, Gunasekaran TI, Belloy ME, Reyes-Dumeyer D, Jülich D, Tayran H, et al. Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer's disease. Acta Neuropathologica. 2024. doi:10.1007/s00401-024-02721-1. PMID: 38598053.

BibTeX

@article{bhattarai2024-38598053,
  author  = {Bhattarai, P. and Gunasekaran, T. I. and Belloy, M. E. and Reyes-Dumeyer, D. and Jülich, D. and Tayran, H. and Yilmaz, E. and Flaherty, D. and Turgutalp, B. and Sukumar, G. and Alba, C. and McGrath, E. M. and others},
  title   = {{Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer's disease}},
  journal = {Acta Neuropathologica},
  year    = {2024},
  doi     = {10.1007/s00401-024-02721-1},
  pmid    = {38598053},
  url     = {https://doi.org/10.1007/s00401-024-02721-1}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that rare variants in the FN1 gene may reduce Alzheimer risk related to APOE ε4, and zebrafish experiments suggested fibronectin loss-of-function reduced gliosis and improved clearance of toxic proteins. The work points to the extracellular matrix as a possible target, but it is early laboratory and genetic research, not a treatment.

Study details

Limitations

The mechanism by which APOE ε4 raises fibronectin is not established; genetic analyses used clinically assessed rather than neuropathologically confirmed individuals, and no autopsy data exist for ε4/ε4 carriers of the rare FN1 variant; mechanistic studies of the variant itself are still needed.

How this study scored 72/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 6 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 71 of the 98 points it could be judged on, which is 72 of 100. Total 72 of 100.71 of the 98 points we could judge = 72 of 100

Published in a leading specialty journal, and it is a case-control study. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 71 of the 98 points we could judge it on, which is 72 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Acta Neuropathologica)
Journal's citation record 3 / 4 Acta Neuropathologica: journal h-index 287 (OpenAlex, 2026-10-29)
Study design 6 / 12 A case-control study
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 3 / 4 7,185 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 59 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 14.8 citations a year over 4 year(s) since 2024
Impact for its field and year 4 / 6 Cited 14.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 3 / 4 Cited 59 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Badri Narayan Vardarajan: h-index 55 (OpenAlex, whole career)
Institution's track record 3 / 3 Stanford University: institution h-index 2,684 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 12 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 38598053)
Free to read — / 2 Access not recorded — left out of this score
Points 71 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 71 of the 98 points we could judge it on is 72 out of 100.
Total 72 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Genetics from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Genetics

See all studies in Genetics →